Efficacy: number of participants who respond to treatment ‐ not reported · adults (aged 18 years+) with depression in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission · adults (aged 18 years+) with depression in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression rating scale scores ‐ not reported · adults (aged 18 years+) with depression in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acceptability ‐ total dropouts · adults (aged 18 years+) with depression in bipolar disorder
It is very uncertain whether riluzole changes acceptability: total dropouts compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults (aged 18 years+) with depression in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acquisition of the ability to sit · children with SMA type I
1 finding from 1 review
Acquisition of the ability to stand · children with SMA type I
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in motor score after two years · children with SMA type I
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events attributable to treatment · children with SMA type I
1 finding from 1 review
Severe adverse events attributable to treatment · children with SMA type I
1 finding from 1 review
Time from birth until death or full‐time ventilation · children with SMA type I
1 finding from 1 review
Acquisition of head control · children with SMA type I
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Short‐term (1 week) percentage change (improvement) in overall speech production · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Cooper 2008 reported 3 speech measures: ICARS speech subscale. Scale from: 0 to 8. Higher scores indicate greater clinical severity Syl... · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Adverse effects (during study) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Economic outcomes · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Intervention not reported
Mortality or tracheostomy at 12 months (pooled hazard ratio)(riluzole 100 mg) · patients with ALS/MND
The intervention showed no clear difference in mortality or tracheostomy at 12 months (pooled hazard… (high certainty).
1 finding from 1 review